A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (NCT05565378)
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Plantation, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (99 Sites)
Showing the first 25 of 99 sites.
- GSK Investigational Site — Plantation, Florida
- GSK Investigational Site — Albuquerque, New Mexico
- GSK Investigational Site — Chattanooga, Tennessee
- GSK Investigational Site — Morgantown, West Virginia
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Cipoletti Rio Negro,
- GSK Investigational Site — Ciudad Autonoma de Buenos Aire,
- GSK Investigational Site — Ciudad Autonoma de Buenos Aire,
- GSK Investigational Site — Florida,
- GSK Investigational Site — Mar del Plata,
- GSK Investigational Site — San Juan,
- GSK Investigational Site — Santa Fe,
- GSK Investigational Site — Wilrijk,
- GSK Investigational Site — Barretos,
- GSK Investigational Site — Porto Alegre,
- GSK Investigational Site — São Paulo,
- GSK Investigational Site — Vitória,
- GSK Investigational Site — Oulu,
- GSK Investigational Site — Tampere,
- GSK Investigational Site — Turku,
- GSK Investigational Site — Vaasa,
- GSK Investigational Site — Bordeaux,
- GSK Investigational Site — Caen,
- GSK Investigational Site — Marseille,
- GSK Investigational Site — Quimper,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer, Non-Small Cell
- Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy — Fountain Valley, California
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) — Ocala, Florida
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs — Dothan, Alabama
Explore by condition: All Lung Cancer, Non-Small Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.